Inhibiting PTEN activity in breast cancer resulted in CPVL promoting resistance to CDK4/6 inhibitors, and CPVL knockdown decreased the tumorigenicity of CDK4/6 inhibitor‐resistant cells in mice. This evidence concerns the gene CDK4 and breast carcinoma.